Home > Back to Publisher > Report Information

Lymphoma Drug Development Strategies at Work - Define Your Competition

BioSeeker Group AB
June 22, 2009
535 Pages - SKU: BIOS2391695

Abstract Table of Contents Related Reports

This report includes defined and up to date development strategies for 176 lymphoma therapeutic drugs (>230 projects) within the portfolio of 106 investigators, from Ceased to Marketed. In total the report assesses five different sub-indications of lymphoma (B-cell lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, T-cell lymphoma and Lymphoma (general)). The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products.

It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:

Providing you with competitive input to the R&D organization to guide development of early
Assisting you to make informed decisions in selecting lymphoma sub-indications that are known to be appropriate for your drug's properties
Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any lymphoma therapeutic drugs to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary
2 About Cancer Highlights
3 Methodologies
4 Table of Contents: 4.1 List of Figures; 4.2 List of Tables
5 Introduction: 5.1 The Scope of this Report; 5.2 Definitions; 5.3 Abbreviations
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment: 6.2 The Cancer Genome Project and Lymphoma Targets
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lymphoma Pipeline?: 7.1 Terminated Drug Target Profiles in Lymphoma; 7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles in the Lymphoma Pipeline; 7.3 Phase III Clinical Development: New and Unique Drug Target Profiles in the Lymphoma Pipeline; 7.4 Phase II Clinical Development: New and Unique Drug Target Profiles the Lymphoma Pipeline; 7.5 Phase I Clinical Development: New and Unique Drug Target Profiles in the Lymphoma Pipeline; 7.6 Preclinical Development: New and Unique Drug Target Profiles in the Lymphoma; Pipeline; 7.7 Development Profiles of All Lymphoma Drug Target Profiles
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Pipeline by Type of Compound: 8.1 Small Molecules; 8.3 Antibodies and Antibody-like Structures; 8.4 Nucleic Acid Therapies; 8.5 Gene Therapy; 8.6 The Competition Through Close Mechanistic Approximation Among Drugs in Lymphoma; 8.7 Compound Strategies based on Sub-Cellular Localization of Lymphoma Drug Targets
9 Selecting a Sub-Indication of Lymphoma for Drug Development: 9.1 B-cell Lymphoma; 9.2 Hodgkin’s Lymphoma; 9.3 Lymphoma (general); 9.4 Non-Hodgkin’s Lymphoma; 9.5 T-cell Lymphoma
10 Portfolio Planning: Competitive Benchmarking of Lymphoma Pipeline by Investigator: 10.1 Abbott; 10.2 Abiogen; 10.3 AEgera; 10.4 Aeterna Zentaris; 10.5 Affimed Therapeutics; 10.6 Aida Pharmaceuticals; 10.7 Alfa Wassermann; 10.8 Alfacell; 10.9 Allos Therapeutics; 10.10 Amgen; 10.11 Anadys Pharmaceuticals; 10.12 Antigenics; 10.13 Archer Biosciences; 10.14 Ariad; 10.15 Ascenta Therapeutics; 10.16 Astellas; 10.17 AstraZeneca; 10.18 Attenuon; 10.19 AVEO; 10.20 Benitec; 10.21 BioCryst Pharmaceuticals; 10.22 Biogen Idec; 10.23 Biolex; 10.24 Boehringer Ingelheim; 10.25 Borean Pharma; 10.26 Bristol-Myers Squibb; 10.27 BTG; 10.28 Calistoga Pharmaceuticals; 10.29 Cell Therapeutics; 10.30 Cephalon; 10.31 Cyclacel; 10.32 Cylene Pharmaceuticals; 10.33 Cytokinetics; 10.34 Daiichi Sankyo; 10.35 Dainippon Sumitomo Pharma; 10.36 Dara Biosciences; 10.37 Dynavax Technologies; 10.38 Eisai; 10.39 Eli Lilly; 10.40 Enzon; 10.41 EpiCept; 10.42 Exelixis; 10.43 Favrille; 10.44 Gemin X Pharmaceuticals; 10.45 Genentech; 10.46 Genmab; 10.47 GenPat77; 10.48 Genta; 10.49 Genzyme; 10.50 GlaxoSmithKline; 10.51 Gloucester Pharmaceuticals; 10.52 Hayashibara; 10.53 Hoffmann-La Roche; 10.54 Human Genome Sciences; 10.55 Hy BioPharma; 10.56 ImClone Systems; 10.57 Immunomedics; 10.58 Inex; 10.59 Innate Pharma; 10.60 InNexus Biotechnology; 10.61 Intracel; 10.62 Italfarmaco; 10.63 Johnson & Johnson; 10.64 Kissei; 10.65 Kyowa Hakko Kirin; 10.66 Ligand; 10.67 Lorus Therapeutics; 10.68 MacroGenics; 10.69 Meda; 10.70 Medarex; 10.71 MedImmune; 10.72 MethylGene; 10.73 Micromet; 10.74 Nektar Therapeutics; 10.75 National Institute of Health (USA); 10.76 Novartis; 10.77 Oncothyreon; 10.78 Pfizer; 10.79 Pharmacyclics; 10.80 PharmaMar; 10.81 ProNAi Therapeutics; 10.82 Reata Pharmaceuticals; 10.83 Rigel; 10.84 Sanofi-Aventis; 10.85 Santaris Pharma; 10.86 SBIO; 10.87 Seattle Genetics; 10.88 Shire; 10.89 SuperGen; 10.90 Takeda; 10.91 Telik; 10.92 Titan Pharmaceuticals; 10.93 TopoTarget; 10.94 Transgene; 10.95 Trubion; 10.96 Vaccinex; 10.97 Vertex Pharmaceuticals; 10.98 VGX Pharmaceuticals; 10.99 Vion Pharmaceuticals; 10.100 VioQuest; 10.101 Wyeth; 10.102 Xencor; 10.103 Yakult Honsha; 10.104 Zenyaku Kogyo; 10.105 ZymoGenetics; 10.106 Non-industrial Source
11 Disclaimer
12 Drug Index
13 Company Index: 4.1 List of Figures; Figure 1: Overall Breakdown of the Included Lymphoma Therapeutic Pipeline by Sub-Indication and Stage of Development; Figure 2: Visualization of Target-Target Interactions Among Lymphoma Drug Targets; Figure 3: The Drug-Protein Interactome of Lymphoma Drugs -Clusters I; Figure 4: The Drug-Protein Interactome of Lymphoma Drugs - Clusters II; Figure 5: Head-to-Head Targeting Interactome of Lymphoma Drugs; Figure 6: Distribution of Compound Types among Lymphoma Drugs; Figure 7: Primary Sub-cellular Localization of Drug Targets; Figure 8: Breakdown of the B-cell Lymphoma Pipeline (I) - Displaying Number of Drugs, Target Profiles and; Investigators by Stage of Development; Figure 9: Breakdown of the B-cell Lymphoma Pipeline (II) - Displaying the Number of Drugs by Compound; Strategy and Stage of Development; Figure 10: Breakdown of the Hodgkin’s Lymphoma Pipeline (I) - Displaying Number of Drugs, Target Profiles; and Investigators by Stage of Development; Figure 11: Breakdown of the Hodgkin’s Lymphoma Pipeline (II) - Displaying the Number of Drugs by Compound; Strategy and Stage of Development; Figure 12: Breakdown of the Lymphoma (general) Pipeline (I) - Displaying Number of Drugs, Target Profiles and; Investigators by Stage of Development; Figure 13: Breakdown of the Lymphoma (general) Pipeline (II) - Displaying the Number of Drugs by Compound; Strategy and Stage of Development; Figure 14: Breakdown of the Non-Hodgkin’s Lymphoma Pipeline (I) - Displaying Number of Drugs, Target; Profiles and Investigators by Stage of Development; Figure 15: Breakdown of the Non-Hodgkin’s Lymphoma Pipeline (II) - Displaying the Number of Drugs by; Compound Strategy and Stage of Development; Figure 16: Breakdown of the T-cell Lymphoma Pipeline (I) - Displaying Number of Drugs, Target Profiles and; Investigators by Stage of Development; Figure 17: Breakdown of the T-cell Lymphoma Pipeline (II) - Displaying the Number of Drugs by Compound; Strategy and Stage of Development; 4.2 List of Tables; Table 1: Competitive Pressure Force Among Lymphoma Drugs; Table 2: Overview of Drug Target Profile Themes; Table of Contents; BioSeeker Group AB © 2009 | www.bioseeker.com; Table 3: Drug Targets of Lymphoma Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the; Cancer Gene Census; Table 4: Identity of Lymphoma Drug Targets with Available Biological Structures; Table 5: Number of Target-Target Interactions among Lymphoma Drug Targets; Table 6: Drug-Protein Interactome Clusters; Table 7: Lymphoma Drug Targets with Available Protein Expression Profiles; Table 8: Pathway Summary; Table 9: Drug Targets without any Identified Assigned Pathways; Table 10: Pathway Profile According to BioCarta of Lymphoma Drug Targets; Table 11: Pathway Profile According to KEGG of Lymphoma Drug Targets; Table 12: Pathway Profile According to NetPath of Lymphoma Drug Targets; Table 13: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness; Table 14: Top Competitive Lymphoma Target Profiles; Table 15: Terminated Drug Target Profiles in Lymphoma; Table 16 New and Unique Lymphoma Targets in Pre-Registration to Marketed; Table 17: New and Unique Lymphoma Targets in Phase III Clinical Development; Table 18: New and Unique Lymphoma Targets in Phase II Clinical Development; Table 19: The Competition Through Close Mechanistic Approximation Between Phase II Lymphoma Drugs; Table 20 New and Unique Lymphoma Targets in Phase I Clinical Development; Table 21: The Competition Through Close Mechanistic Approximation Between Phase I Lymphoma Drugs; Table 22: New and Unique Lymphoma Targets in Preclinical Development; Table 23: The Progression, Maturity and Competitive Comparison of Lymphoma Drug Target Profiles in; Development; Table 24: Overview of Compound Strategy Competition in Lymphoma; Table 25:Overview of the Competitive Landscape of Small Molecular Drugs in Lymhpoma; Table 26: Head-to-head Target Competing Small Molecule Drugs for the Treatment of Lymphoma; Table 27: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs in; Lymphoma; Table 28: The Progression, Maturity and Competitive Comparison of Small Molecule Lymphoma Drug Target; Profiles in Development; Table 29: The Progression, Maturity and Competitive Comparison of Peptide Based Lymphoma Drug Target; Profiles in Development; Table 30:Overview of the Competitive Landscape of Protein Based Drugs in Lymhpoma; Table 31: The Competition Through Close Mechanistic Approximation Between Protein Based Drugs in; Lymphoma; Table 32: The Progression, Maturity and Competitive Comparison of Protein Based Lymphoma Drug Target; Profiles in Development; 4 Lymphoma Drug Development Strategies at Work - Define Your; Competition; 18 Cancer Highlights No 1 Vol 9 2009| BioSeeker Group AB ©; Table 33:Overview of the Competitive Landscape of Antibody Drugs in Lymhpoma; Table 34: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Lymphoma; Table 35: The Progression, Maturity and Competitive Comparison of AntibodyLymphoma Drug Target Profiles in; Development; Table 36:Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs in Lymhpoma; Table 37: The Progression, Maturity and Competitive Comparison of Nucleic Acid Lymphoma Drug Target; Profiles in Development; Table 38: Vectors in Gene Therapy; Table 39: The Progression, Maturity and Competitive Comparison of Gene Therapy Lymphoma Drug Target; Profiles in Development; Table 40: The Competition Through Close Mechanistic Approximation Among Drugs in Lymphoma; Table 41: Compound Strategies based on Sub-Cellular Localization of Lymphoma Drug Targets; Table 42: Competitive Summary of Lymhpoma Drugs by Sub-Indication; Table 43: Players in the Field of B-cell Lymphoma Drug Development and their Compared Pipeline; Table 44: The Competition Through Close Mechanistic Approximation Between B-cell Lymphoma Drugs; Table 45: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in B-cell Lymphoma; Drug Development; Table 46: Players in the Field of Hodgkin’s Lymphoma Drug Development and their Compared Pipeline; Table 47: The Competition Through Close Mechanistic Approximation Between Hodgkin’s Lymphoma Drugs; Table 48: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Hodgkin’s; Lymphoma Drug Development; Table 49: Players in the Field of Lymphoma (general) Drug Development and their Compared Pipeline; Table 50: The Competition Through Close Mechanistic Approximation Between Lymphoma (general) Drugs .; Table 51: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Lymphoma (general; )Drug Development; Table 52: A) Investigators with Multiple Non-Hodgkin’s Lymphoma Drugs in Development B) Investigators with; Ceased, Discontinued or Suspended Drugs; Table 53: Players in the Field of Non-Hodgkin’s Lymphoma Drug Development and their Compared Pipeline .; Table 54: The Competition Through Close Mechanistic Approximation Between Non-Hodgkin’s Lymphoma; Drugs; Table 55: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Non-Hodgkin’s; Lymphoma Drug Development; Table 56: Players in the Field of T-cell Lymphoma Drug Development and their Compared Pipeline; Table 57: The Competition Through Close Mechanistic Approximation Between T-cell Lymphoma Drugs; Table 58: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in T-cell Lymphoma; Drug Development; Table of Contents; BioSeeker Group AB © 2009 | www.bioseeker.com; Table 59: Abbott's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 60: Abiogen's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 61: AEgera's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 62: Aeterna Zentaris’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 63: Affimed Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 64: Aida Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 65: Alfa Wassermann's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 66: Alfacell's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 67: Allos Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 68: Amgen's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 69: Anadys Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 70: Antigenics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 71: Archer Biosciences’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 72: Ariad's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 73: Ascenta Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 74: Astellas’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 75: AstraZeneca's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 76: Attenuon's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 77: AVEO's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 78: Benitec's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 79: BioCryst Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 80: Biogen Idec's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 81: Biolex's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 82: Boehringer Ingelheim's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 83: Borean Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 84: Bristol-Myers Squibb's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 85: BTG's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 86: Calistoga Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 87: Cell Therapeutics' Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 88: Cephalon's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 89: Cyclacel's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 90: Cylene Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 91: Cytokinetics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 92: Daiichi Sankyo's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 93: Dainippon Sumitomo Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 94: Dara Biosciences’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; 20 Cancer Highlights No 1 Vol 9 2009| BioSeeker Group AB ©; Table 95: Dynavax Technologies’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 96: Eisai's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 97: Eli Lilly's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 98: Enzon's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 99: EpiCept's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 100: Exelixis’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 101: Favrille's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 102: Gemin X Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 103: Genentech's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 104: Genmab's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 105: GenPat77's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 106: Genta's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 107: Genzyme's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 108: GlaxoSmithKline's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 109: Gloucester Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 110: Hayashibara's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 111: Hoffmann-La Roche's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 112: Human Genome Sciences’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 113: Hy BioPharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 114: ImClone Systems’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 115: Immunomedics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 116: Inex's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 117: Innate Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 118: InNexus Biotechnology's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 119: Intracel's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 120: Italfarmaco's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 121: Johnson & Johnson's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 122: Kissei's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 123: Kyowa Hakko Kirin's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 124: Ligand's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 125: Lorus Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 126: MacroGenics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 127: Meda's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 128: Medarex's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 129: MedImmune's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 130: MethylGene's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 131: Micromet's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 132: Nektar Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 133: National Institute of Health (USA)'s Included Lymphoma Pipeline Composition and Competitive Fall-; Out; Table 134: Novartis’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 135: Oncothyreon's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 136: Pfizer's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 137: Pharmacyclics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 138: PharmaMar's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 139: ProNAi Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 140: Reata Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 141: Rigel's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 142: Sanofi-Aventis’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 143: Santaris Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 144: SBIO's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 145: Seattle Genetics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 146: Shire's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 147: SuperGen's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 148: Takeda's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 149: Telik's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 150: Titan Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 151: TopoTarget's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 152: Transgene's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 153: Trubion's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 154: Vaccinex's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 155: Vertex Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 156: VGX Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 157: Vion Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 158: VioQuest's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 159: Wyeth's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 160: Xencor's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 161: Yakult Honsha's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 162: Zenyaku Kogyo's Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 163: ZymoGenetics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out; Table 164: Non-industrial source's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Lymphoma Drug Development Strategies at Work - Define Your Competition

Share this report

Other tasks

Research Assistance

Related Markets

Oncology/Hematology Reports

Free Alert Me service